Search results
Results from the WOW.Com Content Network
The lack of a warning sent Bristol Myers' shares up 6.3% at $53.28 in premarket trading on Friday. Bristol Myers obtained drug Cobenfy, also known as KarXT, through its $14 billion takeover of ...
800-290-4726 more ways ... According to one analyst, Cobenfy could reach peak sales of $10 billion -- and that projection was before emraclidine's phase 2 failure. ... Its forward yield of 4.27% ...
Bristol Myers reported that it earned $4.1 billion, or $2 per share, in the third quarter, down from $4.3 billion, or $1.99 a share, a year earlier. ... 800-290-4726 more ways to reach us. Mail ...
Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. [1] It contains xanomeline, a muscarinic agonist; and trospium chloride, a muscarinic antagonist. [1] Xanomeline is a functionally preferring muscarinic M 4 and M 1 receptor agonist. [1]
For the fiscal year 2018,Bristol Myers Squibb reported earnings of US$1.007 billion, with an annual revenue of US$20.776 billion, an increase of 6.9% over the previous fiscal cycle. Bristol-Myers Squibb's shares traded at over $55 per share, and its market capitalization was valued at over US$81.6 billion in October 2018. [91]
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...
As one of the world's biggest pharmaceutical developers, Bristol-Myers isn't going anywhere even if it doesn't grow very rapidly, or even if it goes through a protracted rough patch.
In addition to the support options listed above, paid members also have access to 24/7 phone support by calling 1-800-827-6364. Popular Products. Account; AOL Mail;